Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDI-320
- Development stage
- Phase 2
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PDI-320 is a small molecule drug initially developed by Bausch Health Americas for dermatological indications, specifically targeting skin and musculoskeletal diseases. Its primary indication has been rosacea, where it reached Phase 2 clinical trials. The precise mechanism of action for PDI-320 remains unknown. The drug was also associated with PreCision Dermatology as an inactive organization in its development history[1][2][3].
Beyond the preview
Go deeper on PDI-320.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDI-320.